Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Stallergenes Greer
Stallergenes Greer Announces Publication of Positive Results for PALFORZIA® Phase 3 Study in Peanut-allergic Children Aged 1 to 3 Years
November 20, 2023
From
Stallergenes Greer
Via
Business Wire
Stallergenes Greer Announces Global Agreement With Nestlé Regarding the Peanut Allergy Oral Immunotherapy Treatment Palforzia®
September 04, 2023
From
Stallergenes Greer
Via
Business Wire
Stallergenes Greer Showcases Clinical Relevance and Persisting Benefits of Its Allergen Immunotherapy Treatments at 2023 EAACI Congress
June 09, 2023
From
Stallergenes Greer
Via
Business Wire
Stallergenes Greer Initiates a European Paediatric Phase III Study With Staloral® Birch
May 25, 2023
From
Stallergenes Greer
Via
Business Wire
Stallergenes Greer Foundation to Foster Innovation and Precision Medicine in the Field of Allergy
April 26, 2023
From
Stallergenes Greer
Via
Business Wire
Positive Results of EfficAPSI Real-World Study Confirm Significant Benefit of Sublingual Liquid AIT Treatment on the Onset and Worsening of Asthma in Patients With Allergic Rhinitis
July 02, 2022
From
Stallergenes Greer
Via
Business Wire
Stallergenes Greer Strengthens Precision Medicine Approach in Allergen Immunotherapy With Imperial College London Research Collaboration
January 17, 2022
From
Stallergenes Greer
Via
Business Wire
Stallergenes Greer and Aptar Pharma Announce Partnership to Develop Novel Connected Device for Allergen Immunotherapy Treatment Delivery
October 26, 2021
From
Stallergenes Greer
Via
Business Wire
Stallergenes Greer Launches CORAP (Community for Research in Allergic Patients) Research Programme
October 07, 2021
From
Stallergenes Greer
Via
Business Wire
Stallergenes Greer and Alyatec Announce Research Collaboration to Advance Precision Medicine in Allergen Immunotherapy
July 09, 2021
From
Stallergenes Greer
Via
Business Wire
Stallergenes Greer: Alustal®, the Company’s Subcutaneous Allergen Immunotherapy Treatment (SCIT) Now Available
June 24, 2021
From
Stallergenes Greer
Via
Business Wire
Positive Outcome of European Decentralised Registration Procedure for Stallergenes Greer’s Sublingual House Dust Mite Allergen Immunotherapy Tablet
May 31, 2021
From
Stallergenes Greer
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.